VIR BIOTECHNOLOGY INC (VIR)

Company Profile

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 576 full-time employees. The company went IPO on 2019-10-11. The firm has assembled two technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its clinical development pipeline consists of product candidates targeting hepatitis B virus (HBV), hepatitis delta virus (HDV) and human immunodeficiency virus (HIV). The firm also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). Its pipeline includes VIR-2218, VIR-3434, VIR-1388, VIR-7229, VIR-2482, VIR-2981, VIR-8190, and VIR-1949. VIR-2218 is an investigational HBV-targeting siRNA. VIR-1388 is an investigational HIV T cell vaccine based on human cytomegalovirus (HCMV).

Company Info

VIR BIOTECHNOLOGY INC

1800 Owens Street, Suite 900

San Francisco CALIFORNIA 94158

P: 14159064324

CEO: George Scangos

Employees: 576

Website: https://www.vir.bio/